Source:http://linkedlifedata.com/resource/pubmed/id/14564686
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2003-10-17
|
pubmed:abstractText |
Hormonal replacement therapy (HRT) in postmenopausal women has been shown to increase both triglyceride (TG) and high-density lipoprotein (HDL) cholesterol levels. To better understand the effects of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA), the 2 most commonly prescribed hormones in HRT, on the different subpopulations of TG-rich and HDL lipoproteins, we conducted a placebo-controlled, double-blind, randomized, crossover study consisting of 3 different phases in 14 postmenopausal women. The 3 phases, each 8-week long, included: (1) placebo, (2) CEE 0.625 mg/d, and (3) CEE 0.625 mg/d and MPA 2.5 mg/d. Slight and statistically nonsignificant elevations in TG levels were observed during the CEE treatment. While very-low-density lipoprotein (VLDL) cholesterol levels were not significantly affected by CEE and CEE + MPA, both HRT treatments lowered remnant lipoprotein (RLP) cholesterol (-14% and -37%, respectively). Compared with placebo, CEE caused a significant increase in HDL, HDL(2), apolipoprotein (apo) A-I, LpAI, alpha1, and prealpha1 levels (12%, 27%, 17%, 26%, 60%, and 102%, respectively). The combination therapy blunted the CEE effect on all HDL parameters, resulting in HDL, HDL(2), and LpAI levels being no longer significantly different from placebo. Apo A-I levels and alpha1, and prealpha1 levels were still significantly higher than placebo (+11%, +50%, and +112%, respectively). These results indicate that HRT has beneficial effects on RLP levels and that, while the estrogen component of HRT has a beneficial effect on the HDL subpopulations mostly associated with coronary heart disease (CHD) protection, MPA partially inhibits this effect.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogens, Conjugated (USP),
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Medroxyprogesterone Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0026-0495
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
52
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1330-6
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:14564686-Aged,
pubmed-meshheading:14564686-Apolipoproteins,
pubmed-meshheading:14564686-Cross-Over Studies,
pubmed-meshheading:14564686-Double-Blind Method,
pubmed-meshheading:14564686-Estrogen Replacement Therapy,
pubmed-meshheading:14564686-Estrogens, Conjugated (USP),
pubmed-meshheading:14564686-Female,
pubmed-meshheading:14564686-Humans,
pubmed-meshheading:14564686-Lipoproteins,
pubmed-meshheading:14564686-Lipoproteins, HDL,
pubmed-meshheading:14564686-Medroxyprogesterone Acetate,
pubmed-meshheading:14564686-Middle Aged,
pubmed-meshheading:14564686-Reference Values,
pubmed-meshheading:14564686-Treatment Outcome,
pubmed-meshheading:14564686-Triglycerides
|
pubmed:year |
2003
|
pubmed:articleTitle |
Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high-density lipoproteins.
|
pubmed:affiliation |
Lipid Metabolism Laboratory and the Biostatistics Unit, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|